carbamates has been researched along with Diarrhea in 13 studies
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In part 1 of the COLUMBUS trial, 577 patients with advanced/metastatic BRAF V600-mutant melanoma, untreated or progressed after first-line immunotherapy, were randomised 1:1:1 to 450 mg of encorafenib QD + 45 mg of binimetinib BID (COMBO450) vs 960 mg of vemurafenib BID (VEM) or 300 mg of encorafenib ENCO QD (ENCO300)." | 9.34 | Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. ( Arance, A; Ascierto, PA; de Groot, JWB; Dummer, R; Flaherty, KT; Garbe, C; Gogas, HJ; Gollerkeri, A; Gutzmer, R; Krajsova, I; Liszkay, G; Loquai, C; Mandala, M; Pickard, MD; Robert, C; Schadendorf, D, 2020) |
| "In part 1 of the COLUMBUS trial, 577 patients with advanced/metastatic BRAF V600-mutant melanoma, untreated or progressed after first-line immunotherapy, were randomised 1:1:1 to 450 mg of encorafenib QD + 45 mg of binimetinib BID (COMBO450) vs 960 mg of vemurafenib BID (VEM) or 300 mg of encorafenib ENCO QD (ENCO300)." | 5.34 | Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. ( Arance, A; Ascierto, PA; de Groot, JWB; Dummer, R; Flaherty, KT; Garbe, C; Gogas, HJ; Gollerkeri, A; Gutzmer, R; Krajsova, I; Liszkay, G; Loquai, C; Mandala, M; Pickard, MD; Robert, C; Schadendorf, D, 2020) |
| "Patients with chronic hepatitis C virus (HCV) infection and previous null response to pegylated interferon (Peg-IFN) and ribavirin (RBV) have limited therapeutic options." | 5.16 | Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. ( Chayama, K; Hughes, E; Ikeda, K; Ishikawa, H; Karino, Y; Kumada, H; McPhee, F; Takahashi, S; Toyota, J; Watanabe, H, 2012) |
| " Adverse events occurred in 151 (72." | 2.82 | Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study. ( Berak, H; Bialkowska, J; Bolewska, B; Fleischer-Stępniewska, K; Flisiak, R; Garlicki, A; Halota, W; Horban, A; Jabłkowski, M; Janczewska, E; Jaroszewicz, J; Karpińska, E; Karwowska, K; Knysz, B; Kryczka, W; Lucejko, M; Madej, G; Mozer-Lisewska, I; Nazzal, K; Piekarska, A; Pisula, A; Rostkowska, K; Simon, K; Tomasiewicz, K; Tronina, O; Tudrujek, M; Wawrzynowicz-Syczewska, M; Wiercińska-Drapało, A; Zarębska-Michaluk, D, 2016) |
| "Brecanavir (BCV, 640385) is a novel, potent protease inhibitor (PI) with low nanomolar 50% inhibitory concentrations against PI-resistant human immunodeficiency virus (HIV) in vitro." | 2.72 | Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor. ( Anderson, MT; Fernandez, P; Ford, SL; Johnson, MA; Murray, SC; Reddy, YS; Stein, DS, 2006) |
| " Safety was monitored as clinical adverse events (AEs) and laboratory abnormalities." | 2.70 | Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. ( Lloyd, PP; Lou, Y; Piliero, PJ; Preston, SL; Sadler, BM; Stein, DS, 2001) |
| " Pharmacokinetic sampling was conducted on the last day of each treatment." | 1.33 | Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. ( Borland, J; Ford, SL; Lou, Y; Min, SS; Shelton, MJ; Wire, MB; Xue, ZG; Yuen, G, 2006) |
| "Acute pancreatitis was diagnosed in 5 subjects." | 1.28 | Acute pancreatitis in children with anticholinesterase insecticide intoxication. ( Sofer, S; Weizman, Z, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (23.08) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Ascierto, PA | 1 |
| Dummer, R | 1 |
| Gogas, HJ | 1 |
| Flaherty, KT | 1 |
| Arance, A | 1 |
| Mandala, M | 1 |
| Liszkay, G | 1 |
| Garbe, C | 1 |
| Schadendorf, D | 1 |
| Krajsova, I | 1 |
| Gutzmer, R | 1 |
| de Groot, JWB | 1 |
| Loquai, C | 1 |
| Gollerkeri, A | 1 |
| Pickard, MD | 1 |
| Robert, C | 1 |
| Tongpoo, A | 1 |
| Sriapha, C | 1 |
| Wongvisawakorn, S | 1 |
| Rittilert, P | 1 |
| Trakulsrichai, S | 1 |
| Wananukul, W | 1 |
| Flisiak, R | 1 |
| Janczewska, E | 1 |
| Wawrzynowicz-Syczewska, M | 1 |
| Jaroszewicz, J | 1 |
| Zarębska-Michaluk, D | 1 |
| Nazzal, K | 1 |
| Bolewska, B | 1 |
| Bialkowska, J | 1 |
| Berak, H | 1 |
| Fleischer-Stępniewska, K | 1 |
| Tomasiewicz, K | 1 |
| Karwowska, K | 1 |
| Rostkowska, K | 1 |
| Piekarska, A | 1 |
| Tronina, O | 1 |
| Madej, G | 1 |
| Garlicki, A | 1 |
| Lucejko, M | 1 |
| Pisula, A | 1 |
| Karpińska, E | 1 |
| Kryczka, W | 1 |
| Wiercińska-Drapało, A | 1 |
| Mozer-Lisewska, I | 1 |
| Jabłkowski, M | 1 |
| Horban, A | 1 |
| Knysz, B | 1 |
| Tudrujek, M | 1 |
| Halota, W | 1 |
| Simon, K | 1 |
| Calza, L | 1 |
| Manfredi, R | 1 |
| Pocaterra, D | 1 |
| Chiodo, F | 1 |
| Chayama, K | 1 |
| Takahashi, S | 1 |
| Toyota, J | 1 |
| Karino, Y | 1 |
| Ikeda, K | 1 |
| Ishikawa, H | 1 |
| Watanabe, H | 1 |
| McPhee, F | 1 |
| Hughes, E | 1 |
| Kumada, H | 1 |
| Shelton, MJ | 1 |
| Ford, SL | 2 |
| Borland, J | 1 |
| Lou, Y | 2 |
| Wire, MB | 1 |
| Min, SS | 1 |
| Xue, ZG | 1 |
| Yuen, G | 1 |
| Reddy, YS | 1 |
| Anderson, MT | 1 |
| Murray, SC | 1 |
| Fernandez, P | 1 |
| Stein, DS | 2 |
| Johnson, MA | 1 |
| Harding, JJ | 1 |
| Rixon, KC | 1 |
| Sadler, BM | 1 |
| Piliero, PJ | 1 |
| Preston, SL | 1 |
| Lloyd, PP | 1 |
| Weizman, Z | 1 |
| Sofer, S | 1 |
| Chavarría, AP | 1 |
| Swartzwelder, JC | 1 |
| Villarejos, VM | 1 |
| Zeledón, R | 1 |
| Troutt, HF | 1 |
| Hooper, BE | 1 |
| Harrington, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1B Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in Patients With BRAF-mutant Metastatic Melanoma (The CELEBRATE Study)[NCT04720768] | Phase 1/Phase 2 | 78 participants (Anticipated) | Interventional | 2020-06-04 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for carbamates and Diarrhea
| Article | Year |
|---|---|
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carb | 2020 |
Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Diarrhea; Drug Therap | 2016 |
Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection.
Topics: Adult; Anti-HIV Agents; Carbamates; Diarrhea; Drug Administration Schedule; Drug Resistance, Viral; | 2008 |
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Diarrhea; Drug Therapy, Combination; Female; Genotype; He | 2012 |
Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor.
Topics: Administration, Oral; Adult; Area Under Curve; Benzodioxoles; Capsules; Carbamates; Diarrhea; Dose-R | 2006 |
Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.
Topics: Administration, Oral; Adult; Body Mass Index; Carbamates; Diarrhea; Dose-Response Relationship, Drug | 2001 |
7 other studies available for carbamates and Diarrhea
| Article | Year |
|---|---|
OCCUPATIONAL CARBAMATE POISONING IN THAILAND.
Topics: Adolescent; Adult; Aged; Agricultural Workers' Diseases; Carbamates; Carbofuran; Child; Diarrhea; Fe | 2015 |
Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics.
Topics: Administration, Oral; Adolescent; Adult; Carbamates; Diarrhea; Drug Administration Schedule; Drug Co | 2006 |
Is diarrhoea a major cause of cataract in some tropical countries?
Topics: Acidosis; Animals; Carbamates; Cataract; Cattle; Dehydration; Diarrhea; Eye Proteins; Humans; In Vit | 1981 |
Amprenavir: a new HIV protease inhibitor.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Carbamates; Child; Clinical Trials as Topi | 1999 |
Acute pancreatitis in children with anticholinesterase insecticide intoxication.
Topics: Abdominal Pain; Acute Disease; Amylases; Blood Glucose; Butyrylcholinesterase; Carbamates; Child; Ch | 1992 |
Mebendazole, an effective broad-spectrum anthelmintic.
Topics: Adolescent; Adult; Anthelmintics; Ascariasis; Benzimidazoles; Benzoates; Carbamates; Child; Child, P | 1973 |
Effect of carbadox in experimentally induced salmonellosis of swine.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Body Temperature; Body Weight; Carbamates; Col | 1974 |